Analyzing MediciNova (NASDAQ:MNOV) & BioGaia AB (publ) (OTCMKTS:BIOGY)

BioGaia AB (publ) (OTCMKTS:BIOGY – Get Free Report) and MediciNova (NASDAQ:MNOV – Get Free Report) are both healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their valuation, profitability, institutional ownership, analyst recommendations, risk, earnings and dividends.

Institutional and Insider Ownership

9.9% of MediciNova shares are held by institutional investors. 14.0% of MediciNova shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Get BioGaia AB (publ) alerts:

Profitability

This table compares BioGaia AB (publ) and MediciNova’s net margins, return on equity and return on assets.

Valuation & Earnings

This table compares BioGaia AB (publ) and MediciNova”s top-line revenue, earnings per share and valuation.

BioGaia AB (publ) has higher earnings, but lower revenue than MediciNova. MediciNova is trading at a lower price-to-earnings ratio than BioGaia AB (publ), indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of recent ratings and recommmendations for BioGaia AB (publ) and MediciNova, as reported by MarketBeat.

MediciNova has a consensus price target of $8.33, indicating a potential upside of 499.52%. Given MediciNova’s stronger consensus rating and higher probable upside, analysts clearly believe MediciNova is more favorable than BioGaia AB (publ).

Summary

MediciNova beats BioGaia AB (publ) on 7 of the 12 factors compared between the two stocks.

About BioGaia AB (publ)

(Get Free Report)

BioGaia AB (publ), a healthcare company, provides probiotic products worldwide. The company operates through Pediatrics, Adult Health, and Other segments. The Pediatrics segment offers drops, oral rehydration solutions, and gut health tablets, as well as cultures that are used as an ingredient in infant formula. The Adult Health segment provides gut health tablets and oral health lozenges products, as well as cultures, which are used as an ingredient in a licensee's dairy product. The Other segment provides packaging solutions. It sells its products through distribution partners or through its own distribution channels. BioGaia AB (publ) was founded in 1990 and is based in Stockholm, Sweden.

About MediciNova

(Get Free Report)

MediciNova, Inc., a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. It is developing MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent for treating neurological and other disorders, such as primary and secondary progressive multiple sclerosis, amyotrophic lateral sclerosis, chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and substance dependence and addiction, as well as prevention of acute respiratory distress syndrome, and long COVID. The company's product pipeline also includes MN-221 (bedoradrine), a selective beta-2-adrenergic receptor agonist for the treatment of acute exacerbations of asthma; MN-001 (tipelukast), an orally bioavailable small molecule compound to treat fibrotic and other diseases, including nonalcoholic fatty liver disease and idiopathic pulmonary fibrosis; and MN-029 (denibulin), a tubulin binding agent for treating solid tumor cancers. It has license agreements with Kyorin Pharmaceutical Co., Ltd; Angiogene Pharmaceuticals, Ltd.; and Meiji Seika Kaisha, Ltd. The company was incorporated in 2000 and is headquartered in La Jolla, California.

Receive News & Ratings for BioGaia AB (publ) Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioGaia AB (publ) and related companies with MarketBeat.com's FREE daily email newsletter.